PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Tilray Brands, Inc. (TLRY.TO)
2.000.05 (2.56%)
1.90 - 2.15
0.48 - 2.54
9.88M / 3.06M (Avg.)
-0.59 | -3.40
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
36.29%
Revenue growth exceeding 1.5x Drug Manufacturers - Specialty & Generic median of 0.51%. Joel Greenblatt would verify if operating margins keep pace with this top-line surge.
57.21%
Gross profit growth exceeding 1.5x Drug Manufacturers - Specialty & Generic median of 2.08%. Joel Greenblatt would check if cost advantages or brand equity drive this surge.
-181.24%
Negative EBIT growth while Drug Manufacturers - Specialty & Generic median is 0.00%. Seth Klarman would check if external or internal factors caused the decline.
-181.24%
Negative operating income growth while Drug Manufacturers - Specialty & Generic median is 0.22%. Seth Klarman would check if structural or cyclical issues are at play.
-57.90%
Negative net income growth while Drug Manufacturers - Specialty & Generic median is 0.00%. Seth Klarman would investigate factors dragging net income down.
-53.60%
Negative EPS growth while Drug Manufacturers - Specialty & Generic median is 0.00%. Seth Klarman would explore whether share dilution or profit declines are to blame.
-60.74%
Negative diluted EPS growth while Drug Manufacturers - Specialty & Generic median is 0.00%. Seth Klarman would look for the cause: weakened profitability or heavier share issuance.
0.09%
Share growth above Drug Manufacturers - Specialty & Generic median by more than 2x. Jim Chanos would suspect over-dilution or repeated equity raises.
0.10%
Diluted share change of 0.10% while Drug Manufacturers - Specialty & Generic median is zero. Walter Schloss might see a slight difference in equity issuance policy.
No Data
No Data available this quarter, please select a different quarter.
210.71%
OCF growth of 210.71% while Drug Manufacturers - Specialty & Generic is zero. Walter Schloss might see a modest positive difference, which can compound over time.
-9.01%
Negative FCF growth while Drug Manufacturers - Specialty & Generic median is 0.00%. Seth Klarman would see if others in the industry are still generating positive expansions in free cash.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-52.57%
Negative 10Y OCF/share CAGR while Drug Manufacturers - Specialty & Generic median is 0.00%. Seth Klarman would suspect the firm is failing to keep pace with industry peers.
4994.38%
OCF/share CAGR of 4994.38% while Drug Manufacturers - Specialty & Generic median is zero. Walter Schloss might see a slight advantage that can compound if momentum builds.
1997.53%
3Y OCF/share growth of 1997.53% while Drug Manufacturers - Specialty & Generic median is zero. Walter Schloss might see a modest advantage that could compound if momentum holds.
733.01%
Net income/share CAGR of 733.01% while Drug Manufacturers - Specialty & Generic median is zero. Walter Schloss might see a marginal edge that can grow if the firm invests wisely.
838.92%
5Y net income/share CAGR > 1.5x Drug Manufacturers - Specialty & Generic median of 8.75%. Joel Greenblatt might see superior mid-term capital allocation or product strength.
2455.14%
3Y net income/share CAGR > 1.5x Drug Manufacturers - Specialty & Generic median of 0.04%. Joel Greenblatt might see a recent surge from market share gains or cost synergy.
1295.21%
Equity/share CAGR of 1295.21% while Drug Manufacturers - Specialty & Generic median is zero. Walter Schloss might see a modest advantage in net worth accumulation that could matter long term.
2660.69%
5Y equity/share CAGR > 1.5x Drug Manufacturers - Specialty & Generic median of 6.24%. Joel Greenblatt sees a possible ROE advantage or fewer share issuances boosting book value.
6638.11%
3Y equity/share CAGR > 1.5x Drug Manufacturers - Specialty & Generic median of 8.32%. Joel Greenblatt sees strong short-term returns on equity fueling net worth growth.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-52.39%
AR shrinking while Drug Manufacturers - Specialty & Generic median grows. Seth Klarman sees potential advantage unless it signals declining demand.
43.08%
Inventory growth of 43.08% while Drug Manufacturers - Specialty & Generic median is zero. Walter Schloss checks if we’re preparing for a sales push or risking overstock.
30.23%
Asset growth of 30.23% while Drug Manufacturers - Specialty & Generic median is zero. Walter Schloss sees a slight advantage if expansions yield good returns on capital.
30.94%
BV/share growth of 30.94% while Drug Manufacturers - Specialty & Generic is zero. Walter Schloss sees a slight lead that can expand if sustained over time.
-3.01%
Debt is shrinking while Drug Manufacturers - Specialty & Generic median is rising. Seth Klarman might see an advantage if growth remains possible.
-13.16%
R&D dropping while Drug Manufacturers - Specialty & Generic median is rising. Seth Klarman wonders if we risk ceding future innovation or if peers overspend.
10.77%
SG&A growth far above Drug Manufacturers - Specialty & Generic median. Jim Chanos sees potential red flags in cost management or diminishing returns on spending.